top of page
Amyotrophic Lateral
Sclerosis (ALS)
Also known as Lou Gehrig's disease, ALS is a nervous system disease that weakens muscles and impacts physical function
The facts
30,000
people living with ALS in the US
$250,000
avg out of pocket cost for caring for a person with ALS
2-5
years of avg life expectancy
4
drugs are approved by the FDA for ALS (an orphan disease)
90%
of cases occur without family history
Trial construct vs drug efficacy
Is it the failure of the drug or the failure of the trial construct?
Clinical trial subjects symptomatic for less than 24 months is now the standard in ALS/MND (Motor Neuron Disease) clinical trials.
“This delay in diagnosis is a challenge to providing patients with early treatment. It is estimated that by the time patients experience ALS signs and symptoms, approximately 50 to 70% of the motor neurons are nonfunctional.”
What we're doing to help
• Research collaborations with pharmaceutical and academic organizations
• Pharmaceutical trials to improve the study population selection and improve therapeutic efficacy
• Working to develop and quantify EyeStat to be a new biomarker of ALS
• Preparing to use EyeStat in Telehealth, Point of Care, and home markets to monitor ALS remotely
bottom of page